Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD® (af...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics L...
BD (Becton, Dickinson and Company) , a leading global medical technology company, issued the following statement: BD has reached an agreement with...
Sandoz takes further steps to resolve legacy US generic drug antitrust class action litigation Sandoz US has entered into a settlement agreement with ...
Microbio Co., Ltd. (4128) revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage II...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programs for vibostolima...
Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen recept...
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced long-term results from the OlympiA Phase 3 trial w...
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdege...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (...
Amgen (NASDAQ:AMGN) announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease...
Kite, a Gilead Company (Nasdaq: GILD), announced findings from three new analyses for Yescarta ® (axicabtagene ciloleucel) that demonstrate i...
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
© 2025 Biopharma Boardroom. All Rights Reserved.
